Daihan Pharmaceutical Co.Ltd - Asset Resilience Ratio
Daihan Pharmaceutical Co.Ltd (023910) has an Asset Resilience Ratio of 11.95% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 023910 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Daihan Pharmaceutical Co.Ltd's Asset Resilience Ratio has changed over time. See net asset quality index of Daihan Pharmaceutical Co.Ltd to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Daihan Pharmaceutical Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 023910 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩41.12 Billion | 11.95% |
| Total Liquid Assets | ₩41.12 Billion | 11.95% |
Asset Resilience Insights
- Moderate Liquidity: Daihan Pharmaceutical Co.Ltd has 11.95% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Daihan Pharmaceutical Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Daihan Pharmaceutical Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Daihan Pharmaceutical Co.Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Daihan Pharmaceutical Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 23.79% | ₩77.18 Billion ≈ $52.31 Million |
₩324.41 Billion ≈ $219.85 Million |
-11.66pp |
| 2023-12-31 | 35.45% | ₩104.32 Billion ≈ $70.70 Million |
₩294.25 Billion ≈ $199.41 Million |
+0.31pp |
| 2022-12-31 | 35.14% | ₩97.34 Billion ≈ $65.97 Million |
₩276.98 Billion ≈ $187.71 Million |
-0.22pp |
| 2021-12-31 | 35.36% | ₩96.38 Billion ≈ $65.31 Million |
₩272.54 Billion ≈ $184.70 Million |
+8.69pp |
| 2020-12-31 | 26.67% | ₩67.50 Billion ≈ $45.75 Million |
₩253.09 Billion ≈ $171.52 Million |
+4.89pp |
| 2019-12-31 | 21.78% | ₩53.77 Billion ≈ $36.44 Million |
₩246.85 Billion ≈ $167.29 Million |
+3.63pp |
| 2018-12-31 | 18.15% | ₩42.60 Billion ≈ $28.87 Million |
₩234.75 Billion ≈ $159.09 Million |
+9.43pp |
| 2017-12-31 | 8.72% | ₩16.08 Billion ≈ $10.90 Million |
₩184.40 Billion ≈ $124.97 Million |
+1.04pp |
| 2016-12-31 | 7.68% | ₩12.31 Billion ≈ $8.34 Million |
₩160.31 Billion ≈ $108.64 Million |
+5.89pp |
| 2015-12-31 | 1.79% | ₩2.48 Billion ≈ $1.68 Million |
₩138.83 Billion ≈ $94.08 Million |
-0.37pp |
| 2014-12-31 | 2.16% | ₩2.84 Billion ≈ $1.92 Million |
₩131.61 Billion ≈ $89.19 Million |
-- |
About Daihan Pharmaceutical Co.Ltd
Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions. Daihan Pharmaceutical Co.,Ltd. was founded in 1945 and is headquartered in Seoul, South Korea.